Business Description
Krystal Biotech Inc
NAICS : 325412
SIC : 2836
ISIN : BRK1YSBDR003
Share Class Description:
BSP:K1YS34: BRDRTotal Employee Number:
295Compare
Compare
Traded in other countries / regions
KRYS.USA4KB.Germany1KRYS.ItalyK1YS34.Brazil IPO Date
2026-03-02Description
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 95.52 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 45.02 | |||||
Beneish M-Score | -2.19 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | 27.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 27.33 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.32 | |||||
Quick Ratio | 7.96 | |||||
Cash Ratio | 6.64 | |||||
Days Inventory | 610.06 | |||||
Days Sales Outstanding | 105.1 | |||||
Days Payable | 71.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.3 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.64 | |||||
Operating Margin % | 44.89 | |||||
Net Margin % | 54.82 | |||||
EBITDA Margin % | 46.41 | |||||
FCF Margin % | 58.53 | |||||
OCF Margin % | 61.81 | |||||
ROE % | 20.01 | |||||
ROA % | 18.27 | |||||
ROIC % | 44.78 | |||||
3-Year ROIIC % | 121.38 | |||||
ROC (Joel Greenblatt) % | 79.28 | |||||
ROCE % | 16.23 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 43.29 | |||||
Forward PE Ratio | 0.96 | |||||
PE Ratio without NRI | 43.29 | |||||
Price-to-Owner-Earnings | 49.07 | |||||
PS Ratio | 23.8 | |||||
PB Ratio | 7.52 | |||||
Price-to-Tangible-Book | 7.53 | |||||
Price-to-Free-Cash-Flow | 40.73 | |||||
Price-to-Operating-Cash-Flow | 38.55 | |||||
EV-to-EBIT | 47.48 | |||||
EV-to-Forward-EBIT | 41.83 | |||||
EV-to-EBITDA | 45.93 | |||||
EV-to-Forward-EBITDA | 41.83 | |||||
EV-to-Revenue | 21.31 | |||||
EV-to-Forward-Revenue | 18.65 | |||||
EV-to-FCF | 36.42 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Projected-FCF | 9.12 | |||||
Price-to-Graham-Number | 3.81 | |||||
| Price-to-Net-Current-Asset-Value | 11.14 | |||||
| Price-to-Net-Cash | 14.5 | |||||
Earnings Yield (Greenblatt) % | 2.13 | |||||
FCF Yield % | 2.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Krystal Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 2,328.24 | ||
| EPS (TTM) (R$) | 42.283 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (R$) | - | ||
| 20-Day SMA (R$) | 44.8 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (R$) | 44.8 - 44.8 | ||
| Shares Outstanding (Mil) | 29.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Krystal Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Krystal Biotech Inc Stock Events
| Event | Date | Price (R$) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-17 08:30 | In 159 days | ||
| Annual report for 2026 | 2027-02-17 | In 158 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-17 | In 158 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-03 08:30 | In 53 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 52 days | ||
| Guidance call for 2026 | 2026-09-10 15:55 | 44.80 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-03 08:30 | 44.80 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-03 | 44.80 (+0.00%) | ||
| General meeting for 2026 | 2026-05-15 16:00 | 44.80 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-13 11:20 | 44.80 (+0.00%) |
Show
Entries
Krystal Biotech Inc Frequently Asked Questions
What is Krystal Biotech Inc(BSP:K1YS34)'s stock price today?
The current price of BSP:K1YS34 is R$44.80. The 52 week high of BSP:K1YS34 is R$44.80 and 52 week low is R$44.80.
When is next earnings date of Krystal Biotech Inc(BSP:K1YS34)?
The next earnings date of Krystal Biotech Inc(BSP:K1YS34) is 2026-11-03 Est..
Does Krystal Biotech Inc(BSP:K1YS34) pay dividends? If so, how much?
Krystal Biotech Inc(BSP:K1YS34) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers